Home / Health / AstraZeneca Cancer Drug Combo Shows Promise
AstraZeneca Cancer Drug Combo Shows Promise
1 Sep
Summary
- AstraZeneca's cancer drugs Tagrisso and Orpathys combined improved survival.
- The drug combination was tested as a first-line treatment for lung cancer.
- The combination significantly enhanced progression-free survival in a trial.
AstraZeneca reported on Tuesday that a significant advancement has been made in lung cancer treatment. A late-stage clinical trial conducted in China evaluated a combination of its potent cancer drugs, Tagrisso and Orpathys.
The study focused on the efficacy of this combination as an initial treatment for a particular form of lung cancer. Results demonstrated a notable improvement in progression-free survival for patients receiving the combined therapy.
This development suggests a promising new therapeutic option for individuals diagnosed with this specific type of lung cancer. The improved progression-free survival indicates a potentially longer period before the disease worsens.
